Search - tctmd.com

Displaying 41 - 60 of 269

Sort: Relevancy | Date

News Daily News

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

Michael O'Riordan

July 28, 2023

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Daily News

Enough PCI ‘Versus’ CABG—Time to Focus on Understudied Groups

Michael O'Riordan

May 09, 2023

News Daily News

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

Michael O'Riordan

March 01, 2023

News Daily News

Longer-Term ASCVD Risk Assessment Best for Younger Patients

Michael O'Riordan

February 16, 2023

News Daily News

Top Coronary Artery Disease News of 2022

Yael L. Maxwell

December 29, 2022

News Daily News

Many STEMI Patients Not Treated Within National Time Goals

Michael O'Riordan

November 15, 2022

News Conference News AHA 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Yael L. Maxwell

November 11, 2022

News Conference News AHA 2022

Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI

Shelley Wood

November 10, 2022

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

Todd Neale

November 10, 2022

News Conference News AHA 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Yael L. Maxwell

November 10, 2022

Presentation AHA 2022

Reduction of Lipoprotein(a) With Small Interfering RNA: Results of the OCEAN(a)-DOSE (TIMI 67) Trial

Presenter: Michelle L. O’Donoghue

November 07, 2022

Presentation AHA 2022

Bivalirudin Plus a High-dose Infusion Versus Heparin Monotherapy in Patients with STEMI Undergoing Primary PCI: The BRIGHT-4 Trial

Presenter: Gregg W. Stone

November 07, 2022

Presentation AHA 2022

Comparison of a Precision Care Strategy With Usual Testing To Guide Management Of Stable Patients With Suspected Coronary Artery Disease

Presenter: Pamela S. Douglas

November 07, 2022

News Conference News AHA 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

Shelley Wood

November 06, 2022

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

Shelley Wood

November 06, 2022

News Conference News AHA 2022

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Michael O'Riordan

November 04, 2022

Advertisement

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

LDL Control Remains Poor in CAD Patients: NHANES

Enough PCI ‘Versus’ CABG—Time to Focus on Understudied Groups

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

Longer-Term ASCVD Risk Assessment Best for Younger Patients

Top Coronary Artery Disease News of 2022

Many STEMI Patients Not Treated Within National Time Goals

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Reduction of Lipoprotein(a) With Small Interfering RNA: Results of the OCEAN(a)-DOSE (TIMI 67) Trial

Bivalirudin Plus a High-dose Infusion Versus Heparin Monotherapy in Patients with STEMI Undergoing Primary PCI: The BRIGHT-4 Trial

Comparison of a Precision Care Strategy With Usual Testing To Guide Management Of Stable Patients With Suspected Coronary Artery Disease

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content